AmyloidPETNet:基于端到端深度学习对脑PET影像淀粉样蛋白阳性进行分类
本研究为回顾性研究,纳入2004年末至2023年初的8476例PET扫描(6722例患者),开发端到端深度学习模型AmyloidPETNet,无需依赖有经验阅片医师或结构MRI即可将脑PET扫描分类为淀粉样蛋白阳性或阴性。模型在ADNI 18F-FBP测试集AUC为0.97(95%CI:0.95,0.99),在不同示踪剂数据集中AUC≥0.97。
要点
- 模型可在无需结构MRI和专家阅片的情况下自动分类脑PET淀粉样蛋白阳性/阴性。
- 在ADNI 18F-FBP测试集AUC为0.97(95%CI:0.95,0.99)。
- 医师-模型一致性从A4研究的Cohen κ=0.39到Centiloid项目的Cohen κ=0.93不等。
核心结论
- 所开发的模型能够自动且准确地将脑PET扫描分类为淀粉样蛋白阳性或阴性,无需依赖有经验的阅片者,也无需结构MRI。
研究设计与样本
- 回顾性研究,使用2004年末至2023年初获取的8476例PET扫描(6722例患者),跨五个不同数据集分析。
诊断标准与关键数值
- 扫描淀粉样蛋白阳性基于平均皮质标准化摄取值比(SUVR)截断值判定。
- 模型在ADNI 18F-FBP测试扫描的AUC为0.97(95%CI:0.95,0.99)。
- 模型在开放获取影像研究系列(Open Access Series of Imaging Studies)18F-FBP扫描的AUC为0.95(95%CI:0.93,0.97)。
- 模型在A4研究扫描的AUC为0.98(95%CI:0.98,0.98)。
- 模型应用于不同示踪剂数据集时AUC≥0.97。
临床应用与阅片要点
- 模型在ADNI 18F-FBP数据训练、验证和内部测试,可推广至OASIS 18F-FBP和A4研究数据。
- 医师-模型一致性在A4研究以模棱两可病例为主的样本为fair(Cohen κ=0.39;95%CI:0.16,0.60),在Centiloid项目为almost perfect(Cohen κ=0.93;95%CI:0.86,1.0)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Visual assessment of amyloid PET scans relies on the availability of radiologist expertise, whereas quantification of amyloid burden typically involves MRI for processing and analysis, which can be computationally expensive. Purpose To develop a deep learning model to classify minimally processed brain PET scans as amyloid positive or negative, evaluate its performance on independent data sets and different tracers, and compare it with human visual reads. Materials and Methods This retrospective study used 8476 PET scans (6722 patients) obtained from late 2004 to early 2023 that were analyzed across five different data sets. A deep learning model, AmyloidPETNet, was trained on 1538 scans from 766 patients, validated on 205 scans from 95 patients, and internally tested on 184 scans from 95 patients in the Alzheimer's Disease Neuroimaging Initiative (ADNI) fluorine 18 (18F) florbetapir (FBP) data set. It was tested on ADNI scans using different tracers and scans from independent data sets. Scan amyloid positivity was based on mean cortical standardized uptake value ratio cutoffs. To compare with model performance, each scan from both the Centiloid Project and a subset of the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study were visually interpreted with a confidence level (low, intermediate, high) of amyloid positivity/negativity. The area under the receiver operating characteristic curve (AUC) and other performance metrics were calculated, and Cohen κ was used to measure physician-model agreement. Results The model achieved an AUC of 0.97 (95% CI: 0.95, 0.99) on test ADNI 18F-FBP scans, which generalized well to 18F-FBP scans from the Open Access Series of Imaging Studies (AUC, 0.95; 95% CI: 0.93, 0.97) and the A4 study (AUC, 0.98; 95% CI: 0.98, 0.98). Model performance was high when applied to data sets with different tracers (AUC ≥ 0.97). Other performance metrics provided converging evidence. Physician-model agreement ranged from fair (Cohen κ = 0.39; 95% CI: 0.16, 0.60) on a sample of mostly equivocal cases from the A4 study to almost perfect (Cohen κ = 0.93; 95% CI: 0.86, 1.0) on the Centiloid Project. Conclusion The developed model was capable of automatically and accurately classifying brain PET scans as amyloid positive or negative without relying on experienced readers or requiring structural MRI. Clinical trial registration no. NCT00106899 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Bryan and Forghani in this issue.
引用
- Fan S, Ponisio MR, Xiao P, et al. AmyloidPETNet: Classification of Amyloid Positivity in Brain PET Imaging Using End-to-End Deep Learning. Radiology. 2024. PMID: 38860897. doi:10.1148/radiol.231442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。